Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-06-02 10:38:38 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2213-8587(17)30013-X
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S221385871730013X
其他信息:
出版社: Elsevier BV
作者: Christopher Sorli; Shin-ichi Harashima; George M Tsoukas; Jeffrey Unger; Julie Derving Karsbøl; Thomas Hansen; Stephen C Bain

